Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001628280-25-005761
Filing Date
2025-02-14
Accepted
2025-02-14 16:32:17
Documents
121
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K vnda-20241231.htm   iXBRL 10-K 2348558
2 EX-19.1 vnda12312024ex191.htm EX-19.1 74609
3 EX-23.1 vnda12312024ex231.htm EX-23.1 2380
4 EX-31.1 vnda12312024ex311.htm EX-31.1 10664
5 EX-31.2 vnda12312024ex312.htm EX-31.2 10514
6 EX-32.1 vnda12312024ex321.htm EX-32.1 6680
12 vnda-20241231_g1.gif GRAPHIC 3959
13 vnda-20241231_g2.gif GRAPHIC 4652
14 vnda-20241231_g3.jpg GRAPHIC 31890
15 vnda-20241231_g4.gif GRAPHIC 8078
16 vnda-20241231_g5.jpg GRAPHIC 112897
17 vnda-20241231_g6.jpg GRAPHIC 178034
  Complete submission text file 0001628280-25-005761.txt   11705956

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vnda-20241231.xsd EX-101.SCH 72281
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT vnda-20241231_cal.xml EX-101.CAL 119476
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT vnda-20241231_def.xml EX-101.DEF 282089
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vnda-20241231_lab.xml EX-101.LAB 834170
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vnda-20241231_pre.xml EX-101.PRE 602885
124 EXTRACTED XBRL INSTANCE DOCUMENT vnda-20241231_htm.xml XML 1585013
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

EIN.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-34186 | Film No.: 25629755
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)